Race Oncology (ASX: RAC)
Race Oncology (ASX: RAC) is a specialty pharmaceutical company, whose business model is to pursue later stage drug assets, principally in the cancer field. www.raceoncology.com
Race Oncology confirms positive results from Bisantrene drug trial on patients with advanced acute myeloid leukaemia
Specialty pharmaceutical company Race Oncology (ASX: RAC) has reported positive data from an investigator-initiated Phase II clinical trial of h...
Race Oncology raises $1.8m to advance ‘five-path’ strategy for cancer drug Bisantrene
Pharmaceutical company Race Oncology (ASX: RAC) has come out of a trading halt this morning to announce $1.8 million new equity funding via a st...
Race Oncology appoints biotech entrepreneur Dr Daniel Tillett as CSO
Race Oncology (ASX: RAC) has appointed Nucleics founder Dr Daniel Tillett to its board as chief scientific officer.
Dr Tillett is the founder...
Race Oncology tees up Bisantrene cancer drug trial in Israel
Pharmaceutical company Race Oncology (ASX: RAC) has made incremental progress on its path towards commercialising its first asset Bisantrene, a ...
Race Oncology reaches agreement to make Bisantrene cancer drug available to patients in Israel
Race Oncology (ASX: RAC) will launch its Bisantrene chemotherapy drug in the Middle East after signing an initial three-year distribution and sa...
Race Oncology secures services agreement to pursue Bisantrene cancer drug licensing
Pharmaceutical company Race Oncology (ASX: RAC) has taken a formidable step towards commercialising its leading oncology drug candidate Bisantre...
Race Oncology receives key FDA designation for its Bisantrene drug
Speciality pharmaceutical company Race Oncology (ASX: RAC) has received positive news regarding its flagship acute myeloid leukaemia (AML) drug,...
Race Oncology looks to rediscover effective leukaemia drug
A cancer drug that was largely forgotten about in the 1980’s is on its way back into development courtesy of Race Oncology (ASX: RAC).
The ph...